Ovarian ALK+ diffuse large B-cell lymphoma: a case report and a review of the literature

• Published in: International journal of gynecological pathology Vol. 32; no. 5; p. 471
• Main Authors: Sellami-Dhouib, Rym, Nasfi, Asma, Mejri, Nesrine Turki, Doghri, Raoudha, Charfi, Lamia, Sassi, Samia, Abbes, Imen, Mrad, Karima, Ben Hamida, Naziha, Driss, Maha P, Ben Romdhane, Khaled
• Format: Journal Article
• Language: English
• Published: United States 01.09.2013
• Subjects: Adult; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Biomarkers, Tumor - metabolism; Cell Differentiation; Cyclophosphamide - administration & dosage; Diagnosis, Differential; Doxorubicin - administration & dosage; Fatal Outcome; Female; Humans; Immunohistochemistry; Lymphoma, B-Cell - pathology; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - pathology; Lymphoma, Large B-Cell, Diffuse - surgery; Prednisone - administration & dosage; Receptor Protein-Tyrosine Kinases - metabolism; Vincristine - administration & dosage
• ISSN: 1538-7151
• DOI: 10.1097/PGP.0b013e31826cbd6e

Through this case presentation and a review of the literature, we aim to describe clinical and pathologic features and to distinguish the outcome of these tumors. A 25-year-old woman presented with pelvic pain and an iliac mass. Workup revealed a 53-mm cystic partitioned mass of the left ovary infiltrating the left sacrum. She underwent a left adnexectomy. Gross examination revealed a ruptured ovarian mass. When dissected, it showed grayish cerebroid aspects. Histologic examination revealed a malignant tumor proliferation of the diffuse large cells. An immunohistochemical analysis showed negative results for PLAP, αFP, βHCG, CD117, CK20, and CD30. It also showed lack of B markers and T marker (CD3) and an expression of CD138 and anaplastic lymphoma kinase. The patient was treated by 6 cycles of CHOP chemotherapy and a pelvic radiotherapy. She presented with a 15-cm splenomegaly 26 months later and died of febrile neutropenia. Most patients follow an aggressive disease and are unlikely to respond to the standard.